Skip to content

Solid Biosciences Inc. SLDB Net Investment in Lease

Net Investment in Lease at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
Biogen logo
BiogenBIIB
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Insmed logo
InsmedINSM
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$872.26M+135%
Enterprise value$595.83M+223%
P/S107.8×-9.9×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s net investment in lease?
Solid Biosciences Inc. (SLDB) reported net investment in lease of $21.3M in Q1 2026.
How has Solid Biosciences Inc.'s net investment in lease changed year-over-year?
Solid Biosciences Inc.'s net investment in lease decreased by 10.2% year-over-year, from $23.72M to $21.3M.
What is the long-term trend for Solid Biosciences Inc.'s net investment in lease?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s net investment in lease has grown at a 43.7% compound annual growth rate (CAGR), from $3.58M to $21.92M.